Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3

Clinical Trial Summary

To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.

See also
Status	Clinical Trial	Phase
Completed	`NCT01922076` - Adavosertib and Local Radiation Therapy in Treating Children With Newly Diagnosed Diffuse Intrinsic Pontine Gliomas	Phase 1
Recruiting	`NCT05476939` - Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication 2.0	Phase 3
Terminated	`NCT03330197` - A Study of Ad-RTS-hIL-12 + Veledimex in Pediatric Subjects With Brain Tumors Including DIPG	Phase 1/Phase 2
Terminated	`NCT03690869` - REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma	Phase 1/Phase 2
Active, not recruiting	`NCT02992015` - Gemcitabine in Newly-Diagnosed Diffuse Intrinsic Pontine Glioma	Early Phase 1
Terminated	`NCT01182350` - Molecularly Determined Treatment of Diffuse Intrinsic Pontine Gliomas (DIPG)	Phase 2
Recruiting	`NCT04837547` - PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy	Phase 1
Active, not recruiting	`NCT04911621` - Adjuvant Dendritic Cell Immunotherapy for Pediatric Patients With High-grade Glioma or Diffuse Intrinsic Pontine Glioma	Phase 1/Phase 2
Not yet recruiting	`NCT06333899` - Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion	Early Phase 1
Completed	`NCT00879437` - Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma	Phase 2
Active, not recruiting	`NCT02420613` - Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma	Phase 1
Completed	`NCT03086616` - CED With Irinotecan Liposome Injection Using Real Time Imaging in Children With Diffuse Intrinsic Pontine Glioma (DIPG) (PNOC 009)	Phase 1
Recruiting	`NCT01837862` - A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas	Phase 1/Phase 2
Not yet recruiting	`NCT06093165` - RE-irradiation of Diffuse MIdline Glioma paTients	N/A
Withdrawn	`NCT03632317` - A Study of Panobinostat in Combination With Everolimus for Children and Young Adults With Gliomas	Phase 2
Completed	`NCT02502708` - Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors	Phase 1
Recruiting	`NCT02233049` - Biological Medicine for Diffuse Intrinsic Pontine Glioma (DIPG) Eradication	Phase 2
Completed	`NCT00996723` - Clinical Trial Evaluating the Combination of Vandetanib and Dasatinib During and After Radiation Therapy (RT) in Children With Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG)	Phase 1
Recruiting	`NCT05009992` - Combination Therapy for the Treatment of Diffuse Midline Gliomas	Phase 2
Recruiting	`NCT04049669` - Pediatric Trial of Indoximod With Chemotherapy and Radiation for Relapsed Brain Tumors or Newly Diagnosed DIPG	Phase 2

NCT number	NCT05518838
Study type	Expanded Access
Source	Oblato, Inc.
Contact	Shinwook Kang
Phone	+1-609-734-4329
Email	swkang@oblatoinc.com
Status	Available
Phase

Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms